8 reports

Drug Overview Invokana (canagliflozin; Johnson&Johnson/Mitsubishi Tanabe/Daiichi Sankyo) is a member of the novel sodium-glucose cotransporter-2 (SGLT-2) inhibitor class. SGLT-2 inhibitors do not target insulin secretion or sensitivity and do not interfere with glucose metabolism. They prevent filtered glucose from being...

  • Sodium-Glucose Co-Transporter 2 Inhibitor

Drug Overview Invokana (canagliflozin; Johnson and Johnson/Mitsubishi Tanabe/Daiichi Sankyo) is a member of the novel sodium-glucose cotransporter-2 (SGLT-2) inhibitor class. SGLT-2 inhibitors do not target insulin secretion or sensitivity and do not interfere with glucose metabolism. They prevent filtered glucose...

  • Sodium-Glucose Co-Transporter 2 Inhibitor

Drug Overview: Farxiga

8770 10000 7800

Drug Overview Farxiga (dapagliflozin; AstraZeneca/Ono Pharmaceutical) is a member of the novel sodium-glucose cotransporter-2 (SGLT-2) inhibitor class. It is approved for the treatment of type 2 diabetes and currently in Phase III trials for the treatment of type 1 diabetes, as well as for chronic kidney disease including...

  • Sodium-Glucose Co-Transporter 2 Inhibitor

Drug analysis: Farxiga

8770 10000 7800

Drug Overview Farxiga (dapagliflozin; AstraZeneca) is a member of the novel sodium-glucose cotransporter-2 (SGLT-2) inhibitor class. It is approved for the treatment of type 2 diabetes and currently in Phase III trials for the treatment of type 1 diabetes. SGLT-2 inhibitors do not target insulin secretion or...

  • Sodium-Glucose Co-Transporter 2 Inhibitor
  • Type 2 Diabetes
  • Type 1 Diabetes

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company announced data from a pooled analysis of two phase IIb trials in adults with type ## diabetes (T##D) for an investigational SGLT-## inhibitor, empagliflozin, at the ##th European Association for the Study of Diabetes (EASD) Annual Meeting in Berlin.

  • Therapy
  • Monoclonal Antibody
  • Respiratory Disease
  • Sodium-Glucose Co-Transporter 2 Inhibitor
  • Oncology
  • Arthritis
  • Hormone
  • HIV AIDS
  • Opioid
  • United States
  • World
  • Pharmaceutical Registrations
  • Biologics Production

Following a successful launch for the SGLT-2 inhibitor class – led by Johnson & Johnson's Invokana, which was approved by the FDA in March 2013 – the US diabetes market is poised to evolve further following approval of the first fixed-dose SGLT-2 inhibitor and DPP-4 inhibitor combination...

  • Sodium-Glucose Co-Transporter 2 Inhibitor
  • United States

This year's annual meeting of the American Diabetes Association (ADA) – which will take place June 13-17 in San Francisco – intersects the diabetes market at a notable point of evolution. In the long-acting basal insulin market, the effective duopoly of Sanofi's...

  • Insulin
  • Glucagon Like Peptide 1 Receptor Activator
  • Sodium-Glucose Co-Transporter 2 Inhibitor
  • United States

Having fully acquired the joint venture that it previously operated with Bristol-Myers Squibb, the forthcoming US launch of Farxiga – approved by the FDA last week – will provide AstraZeneca an early opportunity to demonstrate its credentials in the diabetes market. A...

  • Sodium-Glucose Co-Transporter 2 Inhibitor
  • United States